Core Insights - AdaptHealth reported a challenging Q4 2025 with a net revenue of $846.3 million, down 1.2% year over year, attributed mainly to business dispositions in the Wellness at Home segment [5][6] - The company achieved full-year net revenue of $3.245 billion, slightly down 0.5% from the previous year, but with organic growth of 1.7% [6][7] - Management highlighted record patient census in multiple segments, indicating strong operational performance despite revenue declines [5][11] Financial Performance - Q4 net revenue breakdown: - Wellness at Home: $137.3 million, down 16.1% [2] - Diabetes Health: $158.5 million, down 7.4% [3] - Respiratory Health: $178.2 million, up 7.8% [4] - Sleep Health: $372.3 million, up 4.4% [4] - Adjusted EBITDA for 2025 was $616.7 million, with a margin of 19.0%, while Q4 Adjusted EBITDA was $163.1 million, with a margin of 19.3% [8] - Free cash flow for Q4 was $79.3 million, and for the full year, it was $219.4 million, exceeding guidance [9] Operational Developments - The company implemented a new operating model in 2025 to standardize workflows and improve service delivery, resulting in improved setup times for Sleep Health and Respiratory Health [11] - Technology pilots, including AI tools for order intake and patient scheduling, are expected to enhance operational efficiency in the future [12] - A new capitated contract went live in December 2025, covering about 50,000 members, with expectations to serve over 10 million patients nationwide [13] Guidance and Future Outlook - For 2026, AdaptHealth expects revenue growth of 6%-8% over 2025, with organic growth of 7.5%-9.5% [15] - Q1 2026 revenue growth is projected at 2%-3% year over year, with an Adjusted EBITDA margin of approximately 16% [16] - The company anticipates negative free cash flow in Q1 2026, with improvements expected as capitated revenue ramps up [16] Strategic Initiatives - AdaptHealth expanded its footprint with a Hawaii-based HME acquisition, marking its presence in the 48th state [17] - The company received a favorable outcome from CMS regarding competitive bidding, providing long-term stability for its core products [18] - A $14.5 million legal settlement related to a debt collection class action was finalized, with improvements in the company's control environment noted [19][20]

Core Insights - ResMed reported strong revenue growth of 11% in the December quarter, with a GAAP EPS increase of 16% on revenue of $1.42 billion, driven by device and mask sales growth across various regions [2][3][6] Revenue Growth - In Canada and Latin America, constant-currency device sales increased by 8% and masks and other sales rose by 16%, attributed to resupply growth and new patient setups, along with revenue from the VirtuOx acquisition [1] - Excluding the Residential Care Software (RCS) business, sales in the U.S., Canada, and Latin America rose by 11% (6% on a constant currency basis) [2] - Globally, device sales increased by 7% and masks and other sales grew by 14% on a constant currency basis [2] Margin Expansion - The company achieved a gross margin improvement of 110 basis points year-over-year, with an operating margin increase to 36.3% [6][11] - Management expects fiscal 2026 gross margin to be between 62% and 63%, influenced by currency movements [8] Capital Returns - ResMed declared a quarterly dividend of $0.60 per share and repurchased approximately $175 million worth of shares, increasing planned buybacks to over $600 million for fiscal 2026 [5][19][20] Product Development and Innovation - The company is advancing new products, including the FDA-cleared AI recommender Comfort Match and the F30i fabric mask line, with positive feedback from early users [5][12][13] - Management highlighted the importance of GLP-1 medications as a demand tailwind, noting that patients on both GLP-1 and CPAP are 10-11% more likely to start therapy [6][15][16] Operating Expenses - Operating expenses rose, with SG&A increasing by 15% on a headline basis, driven by employee-related expenses and marketing investments [9] - R&D expenses increased by 12% on a headline basis, with expectations to maintain R&D at 6% to 7% of revenue for fiscal 2026 [10] Cash Flow and Financial Position - Cash flow from operations was reported at $340 million, with capital expenditures of $29 million, leaving the company with $1.4 billion in cash and $753 million in net cash [18]